University of Copenhagen

The new AI supercomputer “Gefion”, built on NVIDIA DGX SuperPOD, was launched in Copenhagen, aiming to accelerate research in areas like quantum computing and drug discovery. Funded by a public-private partnership, it will be used by select customers during a pilot phase. Gefion is powered by 1,528 NVIDIA H100 Tensor Core GPUs and hosted in a sustainable data centre. Six pilot projects have been selected to harness its potential.

Denmark launches Gefion, its largest AI supercomputer, powered by NVIDIA's DGX SuperPOD with 1,528 H100 Tensor Core GPUs. Funded by the Novo Nordisk Foundation and the Export and Investment Fund of Denmark, Gefion aims to lead in drug discovery and climate research. Six pilot projects are underway, including rapid weather forecasting and genomic disease analysis. Operated by the Danish Center for AI Innovation, Gefion is housed in a renewable energy-powered data center, positioning Denmark as a leader in sovereign AI capabilities.

NVIDIA CEO Jensen Huang and King Frederik X of Denmark launched Denmark's largest sovereign AI supercomputer, Gefion, powered by 1,528 NVIDIA H100 Tensor Core GPUs. Operated by the Danish Center for AI Innovation, Gefion aims to address global challenges in quantum computing, clean energy, biotechnology, and more. The supercomputer is expected to serve industry, startups, and academia, with a focus on accelerating progress in areas like drug discovery and energy efficiency.

Researchers at the Max Planck Institute for Marine Microbiology, Leibniz-Institute for Baltic Sea Research, and University of Copenhagen developed a cost-effective method using frame-straddling technique to image luminescence lifetimes, enabling high-speed measurements and detailed oxygen dynamics tracking in marine environments.

Drug studies funded by manufacturers report 50% higher efficacy; Tamar Oostrom's research suggests sponsors selectively publish favorable trials, affecting drug use and patient outcomes.

France won't cover Wegovy, an anti-obesity drug, through national insurance, citing cost and need for second-line treatment. Wegovy, a GLP-1 receptor agonist, costs €270-€330/month and is available in several countries but often not covered by insurance. Experts warn of side effects and high costs, advocating for targeted use.

Antag Therapeutics' IND for AT-7687 accepted by FDA, enabling phase 1 trial in healthy lean and obese individuals, exploring AT-7687 and semaglutide combination. Founded in 2017, Antag targets GIP receptor for obesity and cardiovascular disease treatments, with AT-7687 as a peptide GIP receptor antagonist.

Wellcome Leap’s Quantum for Bio program advances teams to Phase 2, offering up to $750,000 for classical simulations of quantum algorithms in healthcare. Finalists include Infleqtion, University of Nottingham, qBraid Co., University of Copenhagen, Harvard University, Stanford University, Algorithmiq Inc., and University of Cambridge. Phase 3 offers up to $5 million for significant quantum advancements in healthcare.

Quantum for Life Centre researchers developed a quantum algorithm to scale up quantum simulators, potentially accelerating drug development by predicting drug behavior in the body before lab trials.

Iterum Therapeutics' oral sulopenem faces FDA approval for uUTIs, with concerns over antibiotic resistance. The drug, a thiopenem antibiotic, previously faced rejection due to insufficient evidence. A Phase III trial showed efficacy in 61.7% of patients, leading to an NDA resubmission. The FDA's PDUFA date is October 25. The approval hinges on responsible use to prevent resistance.